Literature DB >> 16764635

Effects of tacrolimus, cyclosporin A and sirolimus on MG63 cells.

Dörte Krocker1, Carsten Perka, Jens Tuischer, Julia Funk, Stephan Tohtz, Frank Buttgereit, Georg Matziolis.   

Abstract

The reduction in bone mineral density after organ transplantation results in increased morbidity (post-transplantation bone disease) and remains an unsolved problem. A connection with the long-term application of nonglucocorticoidal immunosuppressants is the subject of controversial discussion. We hypothesized that such substances have an influence on the skeletal system on the cellular level by modulating osteoblast differentiation. Therefore, we investigated the effects of tacrolimus, cyclosporin A and sirolimus as representative substances of nonglucocorticoidal immunosuppressants on cell proliferation and expression of bone tissue-specific genes of human osteoblasts (MG63). None of the examined substances affected cell proliferation, but all influenced the gene expression pattern towards change in cell differentiation. In detail, collagen III and XII, matrix metalloproteinase 2, SMAD2, epithelial growth factor receptor, annexin V and osteonectin expression were increased by all of the examined substances. Tacrolimus, cyclosporin A and sirolimus influence intracellular signalling pathways, transmembranous receptors and bone-specific matrix synthesis. They do not have antiproliferative or toxic effects. We postulate that the shown changes of osteoblast differentiation cause post-transplantation disease.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16764635     DOI: 10.1111/j.1432-2277.2006.00319.x

Source DB:  PubMed          Journal:  Transpl Int        ISSN: 0934-0874            Impact factor:   3.782


  7 in total

1.  Preparation and characterization of mesoporous bioactive glass/polycaprolactone nanofibrous matrix for bone tissues engineering.

Authors:  Hsiu-Mei Lin; Yi-Hsuan Lin; Fu-Yin Hsu
Journal:  J Mater Sci Mater Med       Date:  2012-08-09       Impact factor: 3.896

2.  FK506 prevented bone loss in streptozotocin-induced diabetic rats via enhancing osteogenesis and inhibiting adipogenesis.

Authors:  Li-Hua Ni; Ri-Ning Tang; Cheng Yuan; Kai-Yun Song; Li-Ting Wang; Xiao-Chen Wang; Yu-Xia Zhang; Xiao-Liang Zhang; Dong-Dong Zhu; Bi-Cheng Liu
Journal:  Ann Transl Med       Date:  2019-06

3.  Effects of immunosuppressants, FK506 and cyclosporin A, on the osteogenic differentiation of rat mesenchymal stem cells.

Authors:  Yu-Kyung Byun; Kyoung-Hwa Kim; Su-Hwan Kim; Young-Sung Kim; Ki-Tae Koo; Tai-Il Kim; Yang-Jo Seol; Young Ku; In-Chul Rhyu; Yong-Moo Lee
Journal:  J Periodontal Implant Sci       Date:  2012-06-30       Impact factor: 2.614

4.  Potential differentiation ability of gingiva originated human mesenchymal stem cell in the presence of tacrolimus.

Authors:  Dong-Ho Ha; Shiva Pathak; Chul Soon Yong; Jong Oh Kim; Jee-Heon Jeong; Jun-Beom Park
Journal:  Sci Rep       Date:  2016-10-10       Impact factor: 4.379

5.  FGF-23 Levels before and after Renal Transplantation.

Authors:  Domniki Economidou; Spyros Dovas; Aikaterini Papagianni; Panagiotis Pateinakis; Dimitrios Memmos
Journal:  J Transplant       Date:  2009-05-17

6.  FGF23 is associated with early post-transplant hypophosphataemia and normalizes faster than iPTH in living donor renal transplant recipients: a longitudinal follow-up study.

Authors:  Narayan Prasad; Akhilesh Jaiswal; Vikas Agarwal; Shashi Kumar; Saurabh Chaturvedi; Subhash Yadav; Amit Gupta; Raj K Sharma; Dharmendra Bhadauria; Anupama Kaul
Journal:  Clin Kidney J       Date:  2016-07-27

Review 7.  Fibroblast Growth Factor-23-A Potential Uremic Toxin.

Authors:  Piotr Kuczera; Marcin Adamczak; Andrzej Wiecek
Journal:  Toxins (Basel)       Date:  2016-12-08       Impact factor: 4.546

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.